title: Circulating vaccine-derived polioviruses: current state of knowledge.
abstract: Within the past 4 years, poliomyelitis outbreaks associated with circulating vaccine-derived polioviruses (cVDPVs) have occurred in Hispaniola (2000-01), the Philippines (2001), and Madagascar (2001-02). Retrospective studies have also detected the circulation of endemic cVDPV in Egypt (1988-93) and the likely localized spread of oral poliovirus vaccine (OPV)-derived virus in Belarus (1965-66). Gaps in OPV coverage and the previous eradication of the corresponding serotype of indigenous wild poliovirus were the critical risk factors for all cVDPV outbreaks. The cVDPV outbreaks were stopped by mass immunization campaigns using OPV. To increase sensitivity for detecting vaccine-derived polioviruses (VDPVs), in 2001 the Global Polio Laboratory Network implemented additional testing requirements for all poliovirus isolates under investigation. This approach quickly led to the recognition of the Philippines and Madagascar cVDPV outbreaks, but of no other current outbreaks. The potential risk of cVDPV emergence has increased dramatically in recent years as wild poliovirus circulation has ceased in most of the world. The risk appears highest for the type 2 OPV strain because of its greater tendency to spread to contacts. The emergence of cVDPVs underscores the critical importance of eliminating the last pockets of wild poliovirus circulation, maintaining universally high levels of polio vaccine coverage, stopping OPV use as soon as it is safely possible to do so, and continuing sensitive poliovirus surveillance into the foreseeable future. Particular attention must be given to areas where the risks for wild poliovirus circulation have been highest, and where the highest rates of polio vaccine coverage must be maintained to suppress cVDPV emergence.
authors.affiliation: WHO Global Specialized Reference Laboratory, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. omk1@cdc.gov
authors.forename: Olen M
authors.initials: OM
authors.lastname: Kew
authors.forename: Peter F
authors.initials: PF
authors.lastname: Wright
authors.forename: Vadim I
authors.initials: VI
authors.lastname: Agol
authors.forename: Francis
authors.initials: F
authors.lastname: Delpeyroux
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shimizu
authors.forename: Neal
authors.initials: N
authors.lastname: Nathanson
authors.forename: Mark A
authors.initials: MA
authors.lastname: Pallansch
mesh_terms: D002648:Child; D004196:Disease Outbreaks; D004293:Dominican Republic / Q000453:epidemiology; D004534:Egypt / Q000453:epidemiology; D006205:Haiti / Q000453:epidemiology; D006801:Humans; D017589:Immunization Programs; D008270:Madagascar / Q000453:epidemiology; D010679:Philippines / Q000453:epidemiology; D011044:Poland / Q000453:epidemiology; D011051:Poliomyelitis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control / Q000635:transmission; D017955:Poliovirus / Q000235:genetics / Q000302:isolation & purification* / Q000472:pathogenicity; D011055:Poliovirus Vaccine, Oral / Q000009:adverse effects*; D012367:RNA, Viral / Q000032:analysis; D012307:Risk Factors; D017201:Virus Shedding; D014944:World Health Organization
chemical_list: D011055:Poliovirus Vaccine, Oral; D012367:RNA, Viral